A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)
收藏DataCite Commons2026-01-26 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00000447/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
提供机构：
Vivli
创建时间：
2018-10-27
